Alkem Laboratories Q2 FY27 Results: Consolidated Net Profit ₹667 Crore on Total Income of ₹4,686 Crore
- Earnings
- pharmaceuticals

Alkem Laboratories (NSE: ALKEM) reported total income of ₹4,686.20 crore and a consolidated net profit of ₹667.13 crore for the quarter ended 30 Sep 2026, it said in a filing on 12 Nov 2026. Standalone total income was ₹3,193.24 crore and standalone net profit ₹762.48 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹4,686.20 crore, up 14.2% YoY and 20.4% QoQ
- Net profit and EPS: ₹667.13 crore, down 14.4% YoY and up 28.1% QoQ; basic EPS ₹56.48
- Tax expense: ₹331.91 crore, up from ₹116.23 crore a year earlier
- Occlutech: Included from 16 Jul 2026; not comparable with prior periods, per the company
Standalone
The company on its own, without its subsidiaries
- Total income: ₹3,193.24 crore, up 20.8% YoY and 13.9% QoQ
- Net profit and EPS: ₹762.48 crore, down 3.1% YoY and up 33.8% QoQ; basic EPS ₹63.77
- Tax expense: ₹312.67 crore, up from ₹77.05 crore a year earlier
- Discontinued operations: Year-earlier quarter included ₹63.07 crore profit after tax from discontinued operations
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 4,686.20 | 4,104.68 | +14.2% | 3,892.90 | +20.4% | |
| Revenue from operations | 4,551.99 | 4,000.99 | +13.8% | 3,740.15 | +21.7% |
| Other income | 134.21 | 103.69 | +29.4% | 152.75 | -12.1% |
| 667.13 | 779.11 | -14.4% | 520.98 | +28.1% | |
| Profit before tax | 999.65 | 895.83 | +11.6% | 771.99 | +29.5% |
| Finance costs | 57.67 | 35.02 | +64.7% | 46.62 | +23.7% |
| Depreciation | 137.08 | 93.61 | +46.4% | 100.19 | +36.8% |
| Tax expense | 331.91 | 116.23 | +185.6% | 250.50 | +32.5% |
| Net profit margin | 14.24% | 18.98% | -4.74 pp | 13.38% | +0.85 pp |
| EPS, basic (₹) | 56.48 | 63.99 | -11.7% | 43.49 | +29.9% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit fell faster than income. Consolidated total income rose 14.2% YoY, while net profit fell 14.4%, and profit before tax rose 11.6%. The gap sits below pre-tax profit: tax expense of ₹331.91 crore is 33.2% of profit before tax, against ₹116.23 crore a year earlier. The company says net profit declined mainly due to a higher effective tax rate.
Other income is a larger share of the quarter than before. Other income of ₹134.21 crore is 2.9% of total income, and 13.4% of profit before tax of ₹999.65 crore. Revenue from operations rose 13.8% YoY, slower than other income at 29.4%. Finance costs of ₹57.67 crore were 64.7% higher than a year earlier, at 1.2% of total income.
The quarter includes Occlutech from 16 Jul 2026. The company says the results are not comparable with earlier periods. Its EBITDA margin was 22.5%, down 50 bps YoY, which the company attributes to Enzene CDMO operating cost and the Occlutech acquisition. The filing does not give Occlutech's own contribution to revenue or profit for the quarter.
The quarter also carries a ₹35.0 crore exceptional item, a recovery against an investment impaired in the quarter and year ended 31 Mar 2026. Year-earlier consolidated profit was after a ₹14.3 crore exceptional gain on sale of the Indore facility for the six months, per the filing.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 3,193.24 | 2,643.40 | +20.8% | 2,804.35 | +13.9% | |
| Revenue from operations | 3,071.36 | 2,542.03 | +20.8% | 2,667.73 | +15.1% |
| Other income | 121.88 | 101.37 | +20.2% | 136.62 | -10.8% |
| 762.48 | 786.73 | -3.1% | 569.98 | +33.8% | |
| Profit before tax | 1,075.15 | 800.71 | +34.3% | 798.42 | +34.7% |
| Finance costs | 14.71 | 12.75 | +15.4% | 17.52 | -16.0% |
| Depreciation | 58.57 | 58.59 | 0.0% | 57.22 | +2.4% |
| Tax expense | 312.67 | 77.05 | +305.8% | 228.44 | +36.9% |
| Net profit margin | 23.88% | 29.76% | -5.88 pp | 20.32% | +3.55 pp |
| EPS, basic (₹) | 63.77 | 65.80 | -3.1% | 47.67 | +33.8% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone profit before tax rose 34.3% YoY to ₹1,075.15 crore, but net profit fell 3.1% to ₹762.48 crore.
The year-earlier quarter is restated. The Generic Business was transferred to Alkem Wellness Limited effective 01 Oct 2025 and shown as discontinued operations, which included ₹63.07 crore of profit after tax in that quarter. Standalone other income of ₹121.88 crore is 3.8% of total income and 11.3% of profit before tax.
Standalone finance costs of ₹14.71 crore are 0.5% of total income, and standalone depreciation of ₹58.57 crore was flat YoY.
Net cash stood at ₹4,905.40 crore as at 30 Sep 2026, per the company's press release. Consolidated dividend paid in the six months was ₹124.82 crore, up from ₹99.57 crore a year earlier. The statutory auditors issued unmodified review reports, but the consolidated review does not cover five subsidiaries and twenty-eight subsidiaries were not reviewed by their auditors. The Daman formulations facility received an OAI status in August 2026; the company says a response has been submitted and remediation is in progress.
Inference
The filing confirms the Occlutech acquisition, completed on 16 Jul 2026 for a fair value consideration of about ₹10,797.6 million, of which about ₹2,019.3 million is deferred. The purchase price allocation is provisional and goodwill of about ₹7,036.0 million was recognised.
The filing does not say when the deferred consideration will be paid or how much it may change under the share purchase agreement, and it does not give the reason for the higher effective tax rate beyond the new tax regime note.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
